Founded in 2019 by Dr. Rimjhim Agrawal and Laina Emmanuel, BrainSightAI, headquartered in Bengaluru South, Karnataka, is a cutting-edge digital health startup that is pushing the boundaries of neuroscience and brain mapping using AI-based connectomics.
Their flagship product, VoxelBox Explore, is designed to advance brain research and pre-surgical planning by providing personalized brain maps and deep insights into neural connectivity.
Unlocking the Complexity of Brain Mapping
The brain is one of the most intricate organs in the human body, with billions of neurons forming complex networks that govern cognition, emotions, and bodily functions.
Disorders of the brain, such as Alzheimer’s, Parkinson’s, brain tumors, and psychiatric conditions, pose significant challenges to diagnosis, treatment, and recovery.
Traditional brain mapping methods, while effective, are often time-consuming, prone to human error, and require high levels of expertise.
BrainSightAI addresses these challenges by introducing AI-powered solutions that streamline the process of analyzing brain data.
Their platform enables neuroscientists, clinicians, and researchers to quickly and accurately map brain structures and functions, providing insights into various neurological disorders.
VoxelBox Explore: A Leap Forward in Brain Science
VoxelBox Explore uses advanced computational neuroscience techniques to analyze large amounts of brain connectivity and structural data.
In three simple steps—uploading DICOM files, choosing analysis options, and downloading results—users can obtain a detailed analysis of brain networks and tractography.
The platform provides outputs in multiple formats such as heat maps, brain masks, and z-scores, simplifying the interpretation of data for clinical and research purposes.
The key benefits of VoxelBox Explore include:
- AI-informed tumor delineation and intra-tumor segmentation for enhanced surgical planning.
- Generation of functional and cognitive maps within 10 minutes, aiding research on brain tumors, dementia, epilepsy, and other conditions.
- Automatic post-processing of over 30 brain tracts, reducing the time and effort required for manual intervention.
- AI-based probabilistic methods improving sensitivity and specificity in brain tractography.
With this technology, BrainSightAI is transforming how brain disorders are diagnosed and treated, enhancing accuracy by up to 20% in pre-surgical planning and streamlining workflows for clinical researchers.
Journey and Recognition
Since its inception, BrainSightAI has rapidly gained recognition in the healthcare and neuroscience sectors.
It was listed as one of CB Insights’ 150 digital health startups to watch in 2022 and was featured at the G20 Digital Health Exhibition in Goa in 2023, representing India as one of six pioneering startups in the field.
The company has also received a grant from Pfizer in collaboration with Atal Innovation Mission (AIM), NITI Aayog, and IIT Delhi, further solidifying its place as a leader in AI-driven brain research.
Additionally, BrainSightAI has been granted a patent for a system analyzing brain activity using MRI data, a significant milestone in their journey toward revolutionizing brain mapping.
Clinical Trials and Collaborations
BrainSightAI is actively engaged in clinical trials with hospitals across India, such as St. Johns Hospital in Bangalore, Max Hospital in Delhi, and Manipal Hospitals.
These trials focus on using AI-augmented functional connectomics to study conditions like brain tumors, dementia, and traumatic brain injury.
By partnering with leading hospitals, BrainSightAI is collecting critical data to optimize its AI models, making them more robust for clinical and research applications.
The Vision Ahead
Under the leadership of Laina Emmanuel (CEO) and Dr. Rimjhim Agrawal (CTO), BrainSightAI aims to build multi-modal, disease-agnostic tools that can be applied across various neurological conditions.
Their long-term goal is to expand the applications of VoxelBox to cover a wider range of disorders and collaborate with forward-thinking doctors and researchers worldwide.
BrainSightAI’s approach to AI is distinctive, grounded in the belief that objective-driven AI algorithms—designed to learn specific aspects of brain function—will lead to more accurate, explainable, and verifiable models.
Their work represents a new frontier in neuroscience, where machine learning and connectomics converge to make brain research more accessible, precise, and impactful.
Shaping the Future of Neuroscience
BrainSightAI is not just a startup; it is a pioneering force in the future of brain research and treatment.
By offering cutting-edge solutions for brain mapping, advancing surgical planning, and driving clinical research, the company is addressing one of the most complex challenges in medicine: understanding the human brain.
With its visionary leadership and groundbreaking AI technology, BrainSightAI is set to revolutionize how brain disorders are diagnosed, treated, and understood.
